Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.
Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...
Citi referred to the data as a "major scientific advance" for type 1 diabetes patients, highlighting the potential for broader applications in the allogeneic field.